Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs
ID
Morozova, Nataša
(
Avtor
),
ID
Zajc Avramovič, Mojca
(
Avtor
),
ID
Markelj, Gašper
(
Avtor
),
ID
Toplak, Nataša
(
Avtor
),
ID
Avčin, Tadej
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(966,01 KB)
MD5: 2D19D559F428C2EDCA38BD48C0857FDA
URL - Izvorni URL, za dostop obiščite
https://link.springer.com/article/10.1007/s10067-024-07012-4
Galerija slik
Izvleček
Objective: To determine the dynamics of serum levels of TNF-α in patients with juvenile idiopathic arthritis (JIA) treated with anti-TNF-α biological drugs and investigate their association with the disease activity. Methods: We conducted a single-centre, observational cohort study in 98 patients with JIA (30 boys, 68 girls, mean age 11.3 years) treated with anti-TNF-α biological drugs. Clinical examinations and laboratory assessments of serum levels of TNF-α were performed before starting therapy with biological drug and at 6-month intervals afterwards up to 2.5 years. Results: The analysis of serum levels of TNF-α in relation to the disease activity states showed the highest mean serum levels of TNF-α in patients on etanercept who had low disease activity states and in patients on adalimumab who had inactive disease. The correlation analysis in patients with JIA treated with etanercept or adalimumab showed a weak negative correlation between the serum levels of TNF-α and JADAS10 scores (p = 0.007), (r = – 0.177). Conclusion: The assessment of serum levels of TNF-α in children with JIA during treatment with etanercept or adalimumab is not a reliable biomarker of disease activity or immunological remission. Longitudinal measurement of TNF-α has no added clinical value in patients with JIA treated with anti-TNF-α biological drugs.
Jezik:
Angleški jezik
Ključne besede:
adalimumab
,
cytokines
,
etanercept
,
juvenile idiopathic arthritis
,
tumour necrosis factor-alpha
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2024
Št. strani:
Str. 2287-2293
Številčenje:
Vol. 43, iss. 7
PID:
20.500.12556/RUL-160117
UDK:
61
ISSN pri članku:
0770-3198
DOI:
10.1007/s10067-024-07012-4
COBISS.SI-ID:
203660291
Datum objave v RUL:
21.08.2024
Število ogledov:
54
Število prenosov:
3
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Clinical rheumatology
Skrajšan naslov:
Clin. rheumatol.
Založnik:
Springer Nature, International League of Associations for Rheumatology
ISSN:
0770-3198
COBISS.SI-ID:
6910681
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Projekti
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
J3-3061
Naslov:
Klinične, imunološke in genetske značilnosti večorganskega vnetnega sindroma povezanega s COVID-19 pri otrocih in mladostnikih
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
University Medical Centre Ljubljana
Številka projekta:
20190050
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj